Drug Trial Radar · NCT00135226
ASCEND: A Study of Cardiovascular Events iN Diabetes
Last checked: Nov 20, 2026Latest source record: May 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
15,480
Actual
Start
Mar 2005
Primary completion
Mar 12, 2018
Study completion Jul 31, 2037
Sponsor
- Lead sponsor
- University of OxfordAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- British Heart Foundation; Bayer; Medical Research Council; Solvay Pharmaceuticals; Abbott; Mylan; Health Data Research UK; Alzheimer's Research UK; The Macular Society
- First posted
- Aug 25, 2005
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Factorial
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine whether 100mg daily aspirin versus placebo and/or supplementation with 1 gram daily omega-3 fatty acids or placebo prevents "serious vascular events" (i.e. non-fatal heart attack, non-fatal stroke or transient ischaemic attack, or death from vascular causes) in patients with diabetes who are not known to have occlusive arterial disease and to assess the effects on serious bleeding or other adverse events.
Conditions
- Diabetes Mellitus
Interventions
AspirinDrug
Omega-3 Ethyl EstersDrug
Placebo AspirinDrug
Placebo Omega-3 Ethyl EstersDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With First Occurrence of Any Serious Vascular Event (SVE)Time frame: Randomized treatment phase during a mean of 7.4 years
- Number of Participants With First Occurrence of Any Major Bleed (Aspirin Comparison Only)Time frame: Randomized treatment phase during a mean of 7.4 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Clinical Trial Service Unit, NDPH, University of Oxford
Oxford, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.